Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Top Ten Searches
post partum incontinence fibroid hpv colpotomy ovarian cyst curettage endometriosis intrauterine umbilical cordYour Article Summary
See Latest ArticlesActivity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.
BMC Cancer, 09/05/08
Pignata S et al. – Platinum-sensitive mucinous ovarian cancer has a poor response to chemotherapy; studies of this histological subgroup are needed
Methods- Retrospective study of chemotherapy activity in pts with platinum-sensitive recurrent mucinous ovarian cancer
- Eligible pts had recurrent ovarian cancer with >6 mo platinum-free interval
- Review of 20 pts with mucinous histotype and 388 pts with other histotypes
- At baseline, mucinous tumors differed from other tumors for an higher number of pts with lower tumor grading and less advanced FIGO stage
- At recurrence, performance status was worse in mucinous pts (statistically significant difference)
- Secondary cytoreduction for ~ 20% of pts in both groups; fewer pts optimally debulked in the mucinous group
- As second line therapy, single-agent platinum vs platinum based-combination therapy or other non-platinum schedules were more frequent for mucinous cancer pts; also response rate was lower than in non-mucinous pts
- Median time to progression and overall survival: worse for mucinous ovarian cancer
- Mucinous cancer pts received fewer chemotherapy lines
Related Articles
Preventing future cancers by testing women with ovarian cancer for brca mutations
Journal of Clinical Oncology, 10/22/09
Relevance Score: 72%
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
British Journal of Cancer, 11/02/09
Relevance Score: 70%
Unusual Metals Could Forge New Cancer Drug
ScienceDaily, 10/20/09
Relevance Score: 70%
New Drug Aims To Seek And Destroy Many Types Of Cancer
ScienceDaily, 10/07/09
Relevance Score: 70%
New drug aims to seek and destroy many types of cancer
EurekAlert, 10/06/09
Relevance Score: 70%
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Paracentesis in Ovarian Cancer: A Study of the Physiology during Free Drainage of Ascites
Journal of Palliative Medicine, 11/25/09
How to deal with prognostic factors and radiotherapy results in uterine neoplasms with a sarcomatous component
Clinical and Translational Oncology, 11/25/09
Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer
Cancer, 11/25/09
Sponsor
Article Search
Sponsor